Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TY-2136b |
Synonyms | |
Therapy Description |
TY-2136b inhibits ROS1, NTRK, and ALK with activity against resistance mutations, which potentially leads to decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 3400). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TY-2136b | TY2136b|TY 2136b | ALK Inhibitor 33 ROS1 Inhibitor 21 Trk Receptor Inhibitor (Pan) 32 | TY-2136b inhibits ROS1, NTRK, and ALK with activity against resistance mutations, which potentially leads to decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 3400). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05769075 | Phase I | TY-2136b | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | Recruiting | USA | 0 |